Plasmacytoma Overview

Save information for later
Sign Up

Learn About Plasmacytoma

Who are the top Plasmacytoma Local Doctors?
Elite in Plasmacytoma
Dr. Robert Z. Orlowski
Hematology Oncology | Oncology
Elite in Plasmacytoma
Dr. Robert Z. Orlowski
Hematology Oncology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Orlowski is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Orlowski is rated as an Elite provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Youlia M. Kirova
Elite in Plasmacytoma
Youlia M. Kirova
Elite in Plasmacytoma
Youlia M. Kirova
Paris, FR 

Youlia Kirova practices in Paris, France. Kirova is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. Their top areas of expertise are Breast Cancer, Plasmacytoma, Mediastinal Tumor, Hodgkin Lymphoma, and Mastectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Philippe A. Moreau
Elite in Plasmacytoma
Philippe A. Moreau
Elite in Plasmacytoma
Philippe A. Moreau
Head And Neck, 
Nantes, FR 

Philippe Moreau practices in Nantes, France. Mr. Moreau is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

View All Doctors
What are the latest Plasmacytoma Clinical Trials?
A Prospective Single-Arm Clinical Trial of Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
A Prospective Single-Arm Clinical Trial of Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Who is this study for: Patients with relapsed/refractory hematological malignances
Enrollment Status: Recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drugs: Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
Study Phase: Phase 1/Phase 2

Summary: The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center